GRAIL Teams with Priority Health to Expand Galleri
MENLO PARK, Calif., July 16, 2026 GRAIL, Inc. has announced a strategic collaboration with Priority Health, making the Galleri®...
MCED
Advertisement
Johnson & Johnson’s RYBREVANT FASPRO Shows Strong HNSCC Results
CHICAGO, Illinois, May 31, 2026 Johnson & Johnson has reported pivotal results from the Phase 1b/2 OrigAMI-4 study, demonstrating...
GRAIL’s Galleri® Test Increases Cancer Detection 6.5-Fold in PATHFINDER 2 Study
MENLO PARK, California, May 31, 2026 GRAIL, Inc. has unveiled compelling new results from its registrational PATHFINDER 2 study,...
Abbott Cancerguard Advances Multi-Cancer Detection Data
ABBOTT PARK, Ill., April 17, 2026 Abbott has unveiled new data at the AACR Annual Meeting 2026 demonstrating significant...
Advertisement
